Key Highlights

  • Second-quarter net income was $15.7 million versus a $43.7 million loss.
  • Revenue rose 9% to $386.4 million.
  • Adjusted EBITDA was $54.4 million versus a $17.1 million loss.
  • At-risk members were about 105,000, down 10% year over year.

P3 Health Partners (NASDAQ:PIII) enters the week with a very different earnings profile from a year ago. In its second-quarter 2026 results, released on August 10, the physician-enablement and value-based care operator reported net income of $15.7 million, compared with a net loss of $43.7 million in the prior-year quarter. That turnaround, together with revised full-year guidance, is why investors may be revisiting the stock.

Latest Company Context

According to the company's Q2 2026 release, total revenue rose 9% to $386.4 million from $355.8 million. Adjusted EBITDA was $54.4 million, versus a loss of $17.1 million a year earlier, and medical margin reached $97.8 million. Excluding payer settlements and prior-year development, medical margin was $52.9 million, a useful reminder that part of the quarter's strength came from items that may not recur. For the first six months, net income was $18.7 million and adjusted EBITDA $80.2 million.

Membership moved in the opposite direction to profit. At-risk members were about 105,000, down 10% year over year, which the company attributes to intentional network and payer rationalization. Total lives under management were about 133,000, including roughly 28,000 under management service arrangements. Chief executive Dr. Aric Coffman said the business is "now executing according to our plan."

Key Business Drivers

Management's revised 2026 guidance, as reported, calls for adjusted EBITDA of $80 million to $110 million, revenue of $1.5 billion to $1.6 billion, medical margin of $260 million to $300 million, and 102,000 to 106,000 at-risk members. These are management expectations.

The balance sheet is the other major driver. At June 30, cash was $21.3 million, down from $25.0 million at year-end 2025, while total debt was about $120 million, with long-term debt falling to $98.1 million from $228.4 million. Stockholders' equity was $73.2 million, versus a deficit of $155.2 million at the end of 2025, and the company reported $42.7 million of net preferred stock proceeds in the first half. Operating cash flow was negative $89.4 million for the six months.

What Investors Should Watch

Several items may shape sentiment. Second, the risk factors continue to cite the company's ability to continue as a going concern and to maintain debt covenant compliance, so any update on liquidity, covenant headroom or financing may be significant. Third, the pace of operating cash burn relative to a $21.3 million cash balance deserves attention.

Investors may also watch at-risk membership against the 102,000 to 106,000 guidance range, since further declines could pressure revenue, and any commentary on 2027 Medicare Advantage rates and payer contracts. Leadership changes, including a recently listed appointment of a Chief Clinical Officer, may also feature in updates.

A Profit Swing Helped by Items That May Not Recur

P3's profit swing was helped by payer settlements and prior-year development that may not recur, and membership fell as the company rationalised networks and payers. Going-concern risks remain part of the disclosure.